Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Oculus Gets $5.1 Mln Licensing Fee From More Pharma

Oculus Innovative Sciences, Inc. (OCLS: Quote),a California-based nutrition and drug company, Thursday said it received a $5.1 million payment in view of a licensing agreement it executed on August 9, 2012, with More Pharma.

More Pharma had agreed earlier to pay an upfront $5.1 million fee for the exclusive licensing of Oculus' Microcyn-based human healthcare products in Mexico, South/Central America and the Caribbean.

Further, More Pharma will underwrite all costs for regulatory reviews and approval efforts needed for the transition of the marketing and sales effort in the aforementioned countries, said Oculus.

Wednesday, Oculus closed at $0.94 on the Nasdaq.

Click here to receive FREE breaking news email alerts for Oculus Innovative Sciences Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Pro-democracy demonstrations in Hong Kong demanding greater electoral reform entered the sixth day on Wednesday, which also marks China's 65th National Day. Thousands of protesters continue to occupy parts of downtown Hong Kong vowing not to leave until they achieve their goals. They want China... Employment in the U.S. private sector increased by more than expected in the month of September, according to a report released by payroll processor ADP on Wednesday, with employment rising by more than 200,000 jobs for the sixth straight month. After ending each of the two previous sessions modestly lower, stocks may see some further downside in early trading on Wednesday. The major index futures are currently pointing to a moderately lower open for the markets, with the Dow futures down by 34 points.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.